Lyka Labs Ltd (LYKALABS) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 189121,
    "name": "Lyka Labs",
    "stock_name": "Lyka Labs",
    "full_name": "Lyka Labs Ltd",
    "name_url": "stocks-analysis/lyka-labs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "78.00",
    "chg": -3.04,
    "chgp": "-3.75%",
    "dir": -1,
    "prev_price": "81.04",
    "mcapval": "296.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 500259,
    "symbol": "LYKALABS",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE933A01014",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "52.11 k",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/lyka-labs-189121-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0,
      "all_data": []
    }
  },
  "news": {
    "results": [
      {
        "title": "Lyka Labs Stock Falls to 52-Week Low of Rs.77.32 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lyka-labs-stock-falls-to-52-week-low-of-rs7732-amid-continued-downtrend-3749213",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/LykaLabs_priceRelatedfactors_3749213.png",
        "date": "2025-12-05 15:46:35",
        "description": "Lyka Labs has reached a new 52-week low of Rs.77.32 today, marking a significant decline amid a sustained downward trend over recent sessions. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space."
      },
      {
        "title": "Lyka Labs Sees Revision in Market Assessment Amidst Challenging Financial Trends",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/lyka-labs-downgraded-to-strong-sell-amid-deteriorating-fundamentals-and-bearish-outlook-3744045",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/LykaLabs_mojoScore_3744045.png",
        "date": "2025-12-03 11:08:04",
        "description": "Lyka Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and technical outlook. The recent changes in evaluation metrics highlight concerns across several key parameters, signalling a cautious stance from market analysts."
      },
      {
        "title": "Lyka Labs Stock Falls to 52-Week Low of Rs.78.01 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lyka-labs-stock-falls-to-52-week-low-amidst-continued-downtrend-3738340",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/LykaLabs_priceRelatedfactors_3738340.png",
        "date": "2025-12-01 11:07:22",
        "description": "Lyka Labs has reached a new 52-week low of Rs.78.01 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges."
      },
      {
        "title": "Lyka Labs Stock Falls to 52-Week Low of Rs.78.88 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lyka-labs-stock-falls-to-52-week-low-of-rs7888-amidst-continued-downtrend-3717314",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/LykaLabs_priceRelatedfactors_3717314.png",
        "date": "2025-11-20 09:42:27",
        "description": "Lyka Labs has reached a new 52-week low of Rs.78.88 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past six consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector."
      },
      {
        "title": "Lyka Labs Stock Falls to 52-Week Low of Rs.82.9 Amidst Weak Financials",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lyka-labs-stock-falls-to-52-week-low-of-rs829-on-19-nov-2025-3714513",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/LykaLabs_priceRelatedfactors_3714513.png",
        "date": "2025-11-19 09:41:43",
        "description": "Lyka Labs, a company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low price of Rs.82.9 as of today, marking a significant decline in its stock performance over the past year. This development comes amid a backdrop of subdued financial results and valuation metrics that reflect ongoing challenges within the company."
      },
      {
        "title": "Why is Lyka Labs falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-lyka-labs-fallingrising-3712828",
        "imagepath": "",
        "date": "2025-11-18 21:44:32",
        "description": "As of 18-Nov, Lyka Labs Ltd is experiencing a decline in its stock price, currently at Rs. 82.93, which represents a decrease of Rs. 2.62 or 3.06%. The stock has hit a new 52-week low today and has been on a downward trend, losing value for the past four consecutive days, resulting in a total decline of 9.9% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume falling by 4.1% compared to the 5-day average. The stock's performance over the past week and month shows significant underperformance, with declines of 9.78% and 12.15%, respectively, compared to the Sensex, which has seen slight gains.\n\nIn the broader market context, while the Sensex has increased by 0.96% over the past week and 0.86% over the past month, Lyka Labs' performance has been ..."
      },
      {
        "title": "Lyka Labs Falls to 52-Week Low of Rs.85 Amidst Continued Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lyka-labs-stock-falls-to-52-week-low-of-rs85-amidst-continued-downtrend-3710906",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/LykaLabs_priceRelatedfactors_3710906.png",
        "date": "2025-11-18 09:42:55",
        "description": "Lyka Labs has reached a new 52-week low of Rs.85, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced investor sentiment."
      },
      {
        "title": "Lyka Labs Hits 52-Week Low at Rs. 85.55 Amid Market Gains",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/lyka-labs-hits-52-week-low-at-rs-8555-amid-market-gains-3706998",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/LykaLabs_priceRelatedfactors_3706998.png",
        "date": "2025-11-17 10:37:38",
        "description": "Lyka Labs has reached a new 52-week low, reflecting a challenging performance with a year-to-date decline of 39.31%. The stock has underperformed its sector and is trading below key moving averages. Financial metrics indicate significant issues, including a high debt-to-equity ratio and a notable drop in profitability and net sales."
      },
      {
        "title": "Is Lyka Labs overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-lyka-labs-overvalued-or-undervalued-3700048",
        "imagepath": "",
        "date": "2025-11-14 08:08:09",
        "description": "As of 13 November 2025, Lyka Labs has moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company is currently considered overvalued based on its high PE ratio of 156.53, an EV to EBIT of 119.79, and a Price to Book Value of 3.16. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.\n\nIn comparison to its peers, Lyka Labs' PE ratio significantly exceeds that of Cipla, which stands at 22.65, and Dr. Reddy's Labs at 17.86, both of which are classified as attractive. Additionally, while Lyka Labs has a PEG ratio of 0.00, indicating no growth expectations, its peers like Sun Pharma and Divi's Lab are categorized as expensive with PEG ratios of 11.96 and 1.99, respectively. The recent performance of Lyka Labs shows a substantial decline, with a year-to-date return of -43.61%, contrasting sharply with the Se..."
      }
    ],
    "total": 362,
    "sid": "189121",
    "stock_news_url": "https://www.marketsmojo.com/news/lyka-labs-189121"
  },
  "announcements": [
    {
      "caption": "Announcement under Regulation 30 (LODR)-Newspaper Publication",
      "datetime": "13-Nov-2025",
      "details": "As per the letter attached",
      "source": "BSE"
    },
    {
      "caption": "Financial Results For The Quarter 30Th September 2025",
      "datetime": "12-Nov-2025",
      "details": "As per letter atatched",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Held On 12Th November 2025",
      "datetime": "12-Nov-2025",
      "details": "As per letter attachd",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Lyka Labs Stock Falls to 52-Week Low of Rs.77.32 Amidst Continued Downtrend

2025-12-05 15:46:35

Lyka Labs has reached a new 52-week low of Rs.77.32 today, marking a significant decline amid a sustained downward trend over recent sessions. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology space.

Lyka Labs Sees Revision in Market Assessment Amidst Challenging Financial Trends

2025-12-03 11:08:04

Lyka Labs, a microcap player in the Pharmaceuticals & Biotechnology sector, has experienced a revision in its market assessment reflecting ongoing challenges in its financial and technical outlook. The recent changes in evaluation metrics highlight concerns across several key parameters, signalling a cautious stance from market analysts.

Lyka Labs Stock Falls to 52-Week Low of Rs.78.01 Amidst Continued Downtrend

2025-12-01 11:07:22

Lyka Labs has reached a new 52-week low of Rs.78.01 today, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market challenges.

Lyka Labs Stock Falls to 52-Week Low of Rs.78.88 Amidst Continued Downtrend

2025-11-20 09:42:27

Lyka Labs has reached a new 52-week low of Rs.78.88 today, marking a significant decline amid a sustained downward trend. The stock has recorded losses over the past six consecutive sessions, reflecting ongoing pressures within the Pharmaceuticals & Biotechnology sector.

Lyka Labs Stock Falls to 52-Week Low of Rs.82.9 Amidst Weak Financials

2025-11-19 09:41:43

Lyka Labs, a company in the Pharmaceuticals & Biotechnology sector, has reached a new 52-week low price of Rs.82.9 as of today, marking a significant decline in its stock performance over the past year. This development comes amid a backdrop of subdued financial results and valuation metrics that reflect ongoing challenges within the company.

Why is Lyka Labs falling/rising?

2025-11-18 21:44:32

As of 18-Nov, Lyka Labs Ltd is experiencing a decline in its stock price, currently at Rs. 82.93, which represents a decrease of Rs. 2.62 or 3.06%. The stock has hit a new 52-week low today and has been on a downward trend, losing value for the past four consecutive days, resulting in a total decline of 9.9% during this period. Additionally, the stock is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. Investor participation has also decreased, with delivery volume falling by 4.1% compared to the 5-day average. The stock's performance over the past week and month shows significant underperformance, with declines of 9.78% and 12.15%, respectively, compared to the Sensex, which has seen slight gains. In the broader market context, while the Sensex has increased by 0.96% over the past week and 0.86% over the past month, Lyka Labs' performance has been ...

Lyka Labs Falls to 52-Week Low of Rs.85 Amidst Continued Downtrend

2025-11-18 09:42:55

Lyka Labs has reached a new 52-week low of Rs.85, marking a significant decline in its stock price amid a sustained downward trend over recent sessions. The pharmaceutical and biotechnology company’s shares have been under pressure, reflecting a series of financial and market factors that have influenced investor sentiment.

Lyka Labs Hits 52-Week Low at Rs. 85.55 Amid Market Gains

2025-11-17 10:37:38

Lyka Labs has reached a new 52-week low, reflecting a challenging performance with a year-to-date decline of 39.31%. The stock has underperformed its sector and is trading below key moving averages. Financial metrics indicate significant issues, including a high debt-to-equity ratio and a notable drop in profitability and net sales.

Is Lyka Labs overvalued or undervalued?

2025-11-14 08:08:09

As of 13 November 2025, Lyka Labs has moved from an attractive to a fair valuation grade, indicating a shift in its perceived investment quality. The company is currently considered overvalued based on its high PE ratio of 156.53, an EV to EBIT of 119.79, and a Price to Book Value of 3.16. These ratios suggest that the stock is trading at a premium compared to its earnings and book value. In comparison to its peers, Lyka Labs' PE ratio significantly exceeds that of Cipla, which stands at 22.65, and Dr. Reddy's Labs at 17.86, both of which are classified as attractive. Additionally, while Lyka Labs has a PEG ratio of 0.00, indicating no growth expectations, its peers like Sun Pharma and Divi's Lab are categorized as expensive with PEG ratios of 11.96 and 1.99, respectively. The recent performance of Lyka Labs shows a substantial decline, with a year-to-date return of -43.61%, contrasting sharply with the Se...

View All News